Introduction

The worldwide prevalence of Diabetes Mellitus (DM) has risen dramatically over the past two decades, from an estimated 30 million cases in 1985 to 177 million in 2000. Based on current trends, more than 360 million individuals will have diabetes by the year 2030. Although the prevalence of both type 1 and type 2 DM is increasing worldwide, the prevalence of type 2 DM is rising much more rapidly because of increasing obesity and reduced physical activity.[1]

Presently, India has the largest number of people with diabetes in the world as stated in the findings of the International Diabetes Federation, 2007. India clearly leads this list with 40.9 million diabetics. In India, this figure is about to rise to 60.9 million by 2020.[2]

Impaired insulin secretion and insulin resistance are the basic pathophysiological mechanisms responsible for diabetes mellitus. There is well established association between oxidative stress and insulin resistance. The most probable mechanism proposed is when glucose and free fatty acid (FFA) increase in diabetes; they cause oxidative stress along with activation of stress-sensitive signalling pathways. Activation of these pathways, in turn, worsens both insulin action and secretion leading to overt type 2 DM.

Currently insulin and oral antidiabetic agents form the mainstay of treatment in addition to diet and exercise, but these agents are associated with major limitations like:

- Hypoglycemic episodes
- Inability to achieve normoglycemia by themselves. Even in properly selected patients, sulfonylureas may fail (primary
failure: 5-28%) or become ineffective after few months or years (secondary failure: 5-10%) due to progression of insulin resistance or desensitization of receptors.\\cite{3}

- Inability to prevent premature atherosclerosis due to hyperinsulinemia in case of insulin resistance.\\cite{3}

The major limitation in the current therapy of DM is the lack of alternatives to treat patients with insulin resistance.\\cite{4} These patients require very high doses of exogenous insulin and even this has limited effect in improving the quality of life. Various animal studies and clinical trials have favored the use of anti-oxidants in such patients. Anti-oxidants have been shown to improve not only HbA\textsubscript{1c} levels but also glucose uptake in the resistant tissue.\\cite{5}

Various clinical trials have been performed to assess the effects of antioxidants such as omega 3 fatty acid,\\cite{6} alfa lipoic acid and vitamin E on insulin sensitivity. However the above trials are limited by small sample size and none of the trials compared the effects of two or more antioxidants at the same time. Therefore the present study was planned to assess comparative effects of three different antioxidants, on insulin sensitivity reflected by parameters like blood glucose and HbA\textsubscript{1c} in patients of type 2 diabetes mellitus.

HbA\textsubscript{1c} expressed, as the percentage of adult hemoglobin that is glycated, is the most widely used measure to assess glycemic control over the past 90 days. Maintaining HbA\textsubscript{1c} levels in the normal range have been shown to reduce long-term complications of diabetes. HbA\textsubscript{1c} estimation is recommended to determine whether treatment is adequate and also to guide adjustment in drug doses.\\cite{7} The aim of the study is to assess and compare the effects of antioxidants, viz. vitamin E, omega 3 fatty acid and alpha lipoic acid on endogenous insulin sensitivity (reflected by parameters like blood glucose and HbA\textsubscript{1c}) in patients of type 2 Diabetes Mellitus.

### Subjects and Methods

The randomized double-blind, placebo-controlled, prospective, single centre study was conducted in a tertiary care hospital where patients attending the medicine outpatient department/diabetes clinic were recruited for the study. A synopsis of the study protocol was submitted to the institutional ethics committee and approval was obtained. Written informed consent was taken from all the participants.

#### Inclusion criteria

Patients of either sex in the age group of 21-65 years, who are previously diagnosed cases of type 2 diabetes mellitus, were considered. Their fasting blood sugar values during screening were between 110-250 mg/dl. A diagnosis of insulin resistance was made on the basis of NCEP: ATPIII 2001 Criteria for the Metabolic Syndrome.

#### Exclusion criteria

1. Patient with type 2 diabetes mellitus with fasting blood glucose >250 mg/dl or patients who are currently on insulin therapy
2. Patients taking any long term medication except anti-diabetic
3. Patients with major illness

Patients received both Tab. Metformin and Tab. Glimpepiride as oral hypoglycaemic therapy. They were receiving the same oral hypoglycemic medications for at least 6 months. Only vegetarian volunteers were included to avoid any bias.

The patients were categorized randomly into 4 groups.

- Group I $(n=25) \rightarrow$ alpha lipoic Acid group
- Group II $(n=25) \rightarrow$ omega 3 fatty acid group
- Group III $(n=25) \rightarrow$ Vitamin E group
- Group IV $(n=25) \rightarrow$ Placebo group

After patients’ randomization, they were given study medication (alpha lipoic acid, omega 3 fatty acid, Vitamin E or Placebo) for 90 days.

#### Study drugs and doses

- Alpha- lipoic acid 300 mg soft gelatin capsules [Batch number-K117109; expiry date-Jun 2010].
- Ecosapentaenoic acid 180 mg + Docosahexaenoic acid 120 mg soft gelatin capsules [Batch number-G0562808; expiry date-Nov 2010].
- Vitamin E 400 mg soft gelatin capsules [Batch number-G0361908; expiry date-Oct 2010].
- Placebo soft gelatin capsules [Batch number-DCW3701501; expiry date-Dec 2010].

Following parameters were recorded at each visit.

**Visit 1 (Day 0)**

- General examination including height, weight (BMI), waist circumference and blood pressure.
- Blood (Fasting) à Glucose, HbA\textsubscript{1c}

**Visit 2 (Day 90)**

- General examination including height, weight (BMI), waist circumference and blood pressure.
- Blood (Fasting) à Glucose, HbA\textsubscript{1c}
- Adverse drug reaction monitoring

#### Serum Glucose (Fasting)

A fasting sample of blood was collected in a fluoride bulb at each visit for estimation of serum glucose. Blood was centrifuged to separate plasma. The measurement was done by the glucose-oxidase method.

**Blood HbA\textsubscript{1c}**

HbA\textsubscript{1c} was determined by using the cation-exchange resin method.\\cite{7}
Statistical analysis was carried out by paired t-test by using SPSS software version 11 (Chicago, USA).

**Results**

All the four groups were statistically comparable [Table 1]. Though there was decrease in blood glucose level in treatment group as compared to placebo group, the difference was not statistically significant [Table 2]. There was a statistically significant decrease in HbA1c levels in Group I (alpha lipoic Acid), Group II (omega 3 fatty acid) and Group III (vitamin E) (Gr. I = 0.02, Gr. II = 0.03, Gr. III = 0.09) at visit 2 compared to visit 1. Group IV (Placebo) (Gr. IV = 0.21) showed a decrease which was not statistically significant. Maximum decrease was found with omega 3 fatty acid. We also got decrease in placebo group but we believe that this may be because of oral hypoglycaemic drugs [Table 3].

**Discussion**

In the present study the effects of three different antioxidants viz. alpha lipoic acid, omega 3 fatty acid and vitamin E in patients with type 2 DM were evaluated. The present study was a randomized, double blind, placebo controlled trial. Parameters which either directly or indirectly measures endogenous insulin sensitivity were used such as, blood glucose and HbA1c.

Subjects were divided into 4 groups depending upon the medication given. Group I (alpha lipoic Acid), Group II (omega 3 fatty acid) and Group III (vitamin E) showed a reduction in fasting blood glucose levels but this was not statistically significant. Group IV (Placebo) showed an increase in mean values of fasting blood glucose [Table 2].

There was a statistically significant decrease in HbA1c levels in Group I (alpha lipoic Acid), Group II (omega 3 fatty acid) and Group III (vitamin E) at visit 2 compared to visit 1. Group IV (Placebo) also showed a decrease but it was not statistically significant [Table 3]. Though the reduction in blood glucose levels and HbA1c was statistically significant in all the groups, the maximum reduction was found with omega 3 fatty acid. Thus it was the best antioxidant which showed the maximum improvement in type II diabetes mellitus.

Similar results were obtained by Pooya SH and colleagues who studied the effect of omega-3 fatty acids on the concentration of fasting glucose and HbA1c in diabetic patients. They conducted a randomized double-blind, placebo-controlled clinical trial on 81 patients with type 2 DM. Each subject received three capsules of omega-3 fatty acids or a placebo every day for a period of 2 months. They found that due to omega-3 fatty acid supplementation, HbA1c decreased by 0.75% in the treatment group and increased by 0.26% in the control group. However, the changes in fasting blood sugar levels were not significant.

In order to find outcome of vitamin E supplementation, G Paolisso, investigated the potential metabolic benefits deriving

### Table 1: Group wise demographic data mean (SD)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Gr. I (alpha lipoic acid)</th>
<th>Gr. II (omega-3 fatty acid)</th>
<th>Gr. III (vitamin E)</th>
<th>Gr. IV (placebo)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>53.5 (1.4)</td>
<td>54.9 (3.5)</td>
<td>53.6 (1.9)</td>
<td>53.8 (2.1)</td>
<td>0.63</td>
</tr>
<tr>
<td>Males (%)</td>
<td>46.2</td>
<td>53.8</td>
<td>69.2</td>
<td>61.5</td>
<td>0.37</td>
</tr>
<tr>
<td>Females (%)</td>
<td>53.8</td>
<td>46.2</td>
<td>30.8</td>
<td>38.5</td>
<td></td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>82.3 (11.9)</td>
<td>81 (9.5)</td>
<td>81.74 (8.5)</td>
<td>80.5 (10.5)</td>
<td>0.98</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.50 (0.07)</td>
<td>1.59 (0.09)</td>
<td>1.59 (0.08)</td>
<td>1.57 (0.07)</td>
<td>0.48</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>32.26 (2.26)</td>
<td>33.09 (1.84)</td>
<td>32.27 (1.91)</td>
<td>32.47 (2.44)</td>
<td>0.47</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>101.26 (8.57)</td>
<td>100.15 (9.53)</td>
<td>101.11 (6.04)</td>
<td>101.73 (7.55)</td>
<td>0.91</td>
</tr>
</tbody>
</table>

BMI: Body mass index

### Table 2: Change in blood glucose levels in mg/dl (fasting) within the groups from V1 to V2 mean (SD)

<table>
<thead>
<tr>
<th>Groups</th>
<th>Gr. I (alpha lipoic acid)</th>
<th>Gr. II (omega 3 fatty acid)</th>
<th>Gr. III (vitamin E)</th>
<th>Gr. IV (placebo)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit 1</td>
<td>149.73 (29.19)</td>
<td>149.25 (21.58)</td>
<td>150.29 (23.61)</td>
<td>141.96 (22.14)</td>
<td>0.51</td>
</tr>
<tr>
<td>Visit 2</td>
<td>145.53 (21.99)</td>
<td>139.29 (20.86)</td>
<td>144.00 (21.89)</td>
<td>146.88 (23.96)</td>
<td>0.42</td>
</tr>
</tbody>
</table>

*There was a statistically significant decrease in HbA1c levels in Group I (alpha lipoic acid), Group II (omega 3 fatty acid) and Group III (vitamin E) at visit 2 compared to visit 1. Maximum decrease was found with omega 3 fatty acid

### Table 3: Change in serum HbA1c as percentage of the total Hb within the groups from V1 to V2 mean (SD)

<table>
<thead>
<tr>
<th>Groups</th>
<th>Gr. I (alpha lipoic acid)</th>
<th>Gr. II (omega 3 fatty acid)</th>
<th>Gr. III (vitamin E)</th>
<th>Gr. IV (placebo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit 1</td>
<td>11.49 (1.38)</td>
<td>11.36 (1.61)</td>
<td>11.44 (1.86)</td>
<td>11.18 (1.45)</td>
</tr>
<tr>
<td>Visit 2</td>
<td>9.96 (1.61)</td>
<td>9.53 (1.3)</td>
<td>9.90 (1.75)</td>
<td>10.77 (1.94)</td>
</tr>
</tbody>
</table>

*P<0.05, **P<0.01 for comparison between visit 1 and visit 2
from daily vitamin E administration in type II diabetic patients. They found that long term vitamin E administration reduced plasma glucose, triglycerides, FFAs, total cholesterol, low-density lipoprotein cholesterol, and apoprotein B levels but did not affect beta-cell response to glucose. HbA1c levels were also significantly lowered.

**Role of antioxidants**

It has long been suspected, but only recently demonstrated, that the consumption of fruits and vegetables rich in vitamin and other antioxidants can increase overall antioxidant status. In studies of humans and rodents, dietary supplementation with antioxidants is associated with decreased risk of type 2 DM and induces changes that could be beneficial in reducing insulin resistance and protecting vascular endothelium. Primary among these are vitamin E (alpha-tocopherol), Alpha lipoic acid (thiotic acid) and omega 3 fatty acid.

In the GK rat, a model for type 2 DM, vitamin E supplementation significantly improved glycemic control, possibly by minimizing free radical damage to the pancreatic β-cells. Another study using the obese Zucker rat, an animal that exhibits many of the features of type 2 DM showed improvements in glucose metabolism and insulin action by addition of vitamin E that was mediated by a reduction in oxidative stress. They found that glucose-stimulated hyper-insulinemia and lipid peroxidation in the obese Zucker rat could be significantly reduced with dietary vitamin E.

Alpha lipoic acid, an essential cofactor of alpha-oxoacid dehydrogenase complexes, is also a potent lipophilic free radical scavenger. Alpha lipoic acid was found to increase glucose transport in muscle cells in culture by stimulating translocation of GLUT4 from internal pools to the plasma membrane. In cultured adipocytes, treatment with ALA protected the insulin receptor from oxidative damage, maintaining its functional integrity. Konrad, et al., used cell cultures consisting of different isoforms of p38 MAPK (p38 mitogen-activated protein kinase) in L6 GLUT4 myocytes. They demonstrated that Alpha lipoic acid was able to increase the plasma membrane content of GLUT4 and stimulate glucose uptake in L6 GLUT4 myocytes to a similar extent as insulin. They further suggested that alpha lipoic acid stimulates glucose uptake by translocating and regulating the intrinsic activity of GLUT4. They concluded that alpha lipoic acid enhanced glucose uptake and GLUT4 translocation in L6 myocytes, mimicking insulin action.

Ingestion of PUFA-rich diets, particularly enriched in omega 3 fatty acid, has been shown to have anti-obesity effects and to facilitate insulin action through a number of metabolic effects. Ingestion of both omega 6 and omega 3 fatty acid has been demonstrated to suppress hepatic lipogenesis, reduce the hepatic output of triglycerides, enhance ketogenesis, and induce fatty acid oxidation in both the liver and the skeletal muscle. Insulin sensitivity may improve as a result of the effects of fatty acid intake on membrane fluidity. The improvement in glucose uptake after membrane enrichment with PUFA is apparently related to an increase in the residency time of GLUT4 in the plasma membrane, which leads to an expansion of the intracellular pool of glucose-6-phosphate and to increased skeletal muscle glycogen synthesis.

The results of this study demonstrate that antioxidants alpha lipoic acid, omega 3 fatty acid and vitamin E showed encouraging decrease in blood glucose and HbA1c with no adverse effect and these antioxidants may be used in patients with type 2 diabetes mellitus. Depending upon the cost benefit analysis we found vitamin E to be the most cost effective even though the maximum improvement in blood glucose and HbA1c was with omega 3 fatty acid.

**Summary and Conclusions**

Currently many drugs are used to treat type 2 diabetes mellitus. Most of these drugs either improve the insulin secretion by the pancreas or decrease the secretion of glucose by the liver. However the basic pathology of insulin resistance goes unanswered. Antioxidants by their unique mechanisms of action can be used to tackle this problem in addition to anti-diabetic drugs in any of the groups.

The results of this study demonstrate that antioxidants alpha lipoic acid, omega 3 fatty acid and vitamin E showed encouraging decrease in blood glucose and HbA1c with no adverse effect and these antioxidants may be used in patients with type 2 diabetes mellitus. However further study with larger sample size and longer duration of treatment is required to definitely establish the role of anti-oxidants in patients with type 2 diabetes mellitus. Depending upon the cost benefit analysis we found vitamin E to be the most cost effective even though the maximum improvement in blood glucose and HbA1c was with omega 3 fatty acid. But most importantly, since the antioxidants differed in their effects on parameters of insulin sensitivity, combining these drugs might prove as an attractive option in patients with type 2 diabetes mellitus.

**References**

5. Montonen J, Knekt P, Järvinen R, Reunanen A. Dietary...


Source of Support: Nil. Conflict of Interest: None declared.